IMUNON, Inc. announced on May 15, 2025, new data from its Phase 1 proof-of-concept clinical trial of IMNN-101, a DNA plasmid vaccine for COVID-19. The results demonstrated IMNN-101’s durability of protection at six months after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant.
The vaccine induced up to a 3-fold median increase in serum neutralizing antibody (NAb) titers from baseline at six months, with stronger immune responses observed in the two higher dose cohorts. The highest individual increase among participants was 8-fold from baseline.
IMNN-101 continued to show a favorable safety profile with no serious adverse effects reported. These findings further validate the PlaCCine technology platform's potential, highlighting its advantages in durability, temperature stability, and manufacturing ease compared to mRNA vaccines. IMUNON is in discussions regarding strategic partnerships for the PlaCCine platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.